GRI Bio, Inc. (NASDAQ:GRI – Get Free Report)’s share price traded down 2.8% on Tuesday . The company traded as low as 0.43 and last traded at 0.45. 143,300 shares changed hands during trading, a decline of 77% from the average session volume of 616,372 shares. The stock had previously closed at 0.46.
GRI Bio Stock Performance
The company has a market cap of $1.43 million, a P/E ratio of -0.01 and a beta of -1.77. The stock’s fifty day moving average price is 0.74 and its two-hundred day moving average price is 3.34.
About GRI Bio
GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.
See Also
- Five stocks we like better than GRI Bio
- Short Selling: How to Short a Stock
- Charles Schwab Fortifies its Uptrend on EPS Beat
- How to Calculate Stock Profit
- Lockheed Martin Stock Aims for a Fresh All-Time High
- How to Invest in the Best Canadian Stocks
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for GRI Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRI Bio and related companies with MarketBeat.com's FREE daily email newsletter.
